Alpha 2.0
Login Register
» Authors » Colin Reisner

Colin Reisner

Explore the profile of Colin Reisner including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 1311
Followers 0
Related Specialties
Pulmonary Medicine
Pharmacology
Critical Care
Top 10 Co-Authors
Patrick Darken
Earl St Rose
Shahid Siddiqui
Fernando J Martinez
Gary T Ferguson
Andrea Maes
Paul Dorinsky
Klaus F Rabe
Michael Golden
Ubaldo J Martin
Published In
Int J Chron Obstruct Pulmon Dis
Respir Med
Respir Res
Chest
Am J Respir Crit Care Med
Affiliations
Soon will be listed here.
Recent Articles
1.
Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial
Chastre J, Francois B, Bourgeois M, Komnos A, Ferrer R, Rahav G, et al.
Crit Care . 2022 Nov; 26(1):355. PMID: 36380312
Background: Ventilator-associated pneumonia caused by Pseudomonas aeruginosa (PA) in hospitalised patients is associated with high mortality. The effectiveness of the bivalent, bispecific mAb MEDI3902 (gremubamab) in preventing PA nosocomial pneumonia...
2.
Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward
Martinez F, Agusti A, Celli B, Han M, Allinson J, Bhatt S, et al.
Am J Respir Crit Care Med . 2021 Oct; 205(3):275-287. PMID: 34672872
Chronic obstructive pulmonary disease (COPD) is the end result of a series of dynamic and cumulative gene-environment interactions over a lifetime. The evolving understanding of COPD biology provides novel opportunities...
3.
A randomized controlled trial of glycopyrrolate administered by metered dose inhaler in patients with uncontrolled asthma despite ICS/LABA treatment
Kerwin E, Dorinsky P, Patel M, Rossman K, Reisner C, Maes A, et al.
J Asthma . 2021 Aug; 59(7):1420-1432. PMID: 34338132
Objective: To evaluate the efficacy and safety of three doses of glycopyrrolate metered dose inhaler (GP MDI) in patients with uncontrolled asthma despite treatment with inhaled corticosteroid/long-acting β-agonists (ICS/LABA) with...
4.
Dose-Ranging and Cumulative Dose Studies of Albuterol Sulfate MDI in Co-Suspension Delivery™ Technology (AS MDI; PT007) in Patients with Asthma: the ASPEN and ANTORA Trials
Cappelletti C, Maes A, Rossman K, Gillen M, LaForce C, Kerwin E, et al.
Clin Drug Investig . 2021 Jun; 41(6):579-590. PMID: 34089147
Background And Objectives: Co-suspension Delivery™ Technology has been developed for the administration of albuterol sulfate pressurised inhalation suspension via metered-dose inhaler (AS MDI, PT007). We assessed the efficacy and safety...
5.
Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Exacerbation Outcomes in Patients with COPD without a Recent Exacerbation History: A Subgroup Analysis of KRONOS
Martinez F, Ferguson G, Bourne E, Ballal S, Darken P, Aurivillius M, et al.
Int J Chron Obstruct Pulmon Dis . 2021 Feb; 16:179-189. PMID: 33542624
Purpose: In the Phase III, 24-week KRONOS study (NCT02497001), triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) reduced exacerbation rates versus glycopyrrolate/formoterol fumarate (GFF) MDI in patients with...
6.
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study
Martinez F, Rabe K, Ferguson G, Wedzicha J, Singh D, Wang C, et al.
Am J Respir Crit Care Med . 2020 Nov; 203(5):553-564. PMID: 33252985
In the phase III, 52-week ETHOS (Efficacy and Safety of Triple Therapy in Obstructive Lung Disease) trial in chronic obstructive pulmonary disease (COPD) (NCT02465567), triple therapy with budesonide/glycopyrrolate/formoterol fumarate (BGF)...
7.
Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe chronic obstructive pulmonary disease
Gon Y, Nishi K, Sato K, Maes A, Siddiqui S, Hayashi N, et al.
Respir Investig . 2020 Sep; 59(1):135-144. PMID: 32917556
Background: PINNACLE-4 evaluated the efficacy and safety of the long-acting muscarinic antagonist/long-acting β-agonist fixed-dose combination glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in patients from Asia, Europe, and the USA...
8.
Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD
Rabe K, Martinez F, Ferguson G, Wang C, Singh D, Wedzicha J, et al.
N Engl J Med . 2020 Jun; 383(1):35-48. PMID: 32579807
Background: Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose...
9.
Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies
Martinez F, Lipworth B, Rabe K, Collier D, Ferguson G, Sethi S, et al.
Respir Res . 2020 May; 21(1):128. PMID: 32450869
Background: The Phase III PINNACLE studies assessed the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI), a dual long-acting bronchodilator for chronic obstructive pulmonary disease (COPD). Here...
10.
Functional respiratory imaging assessment of glycopyrrolate and formoterol fumarate metered dose inhalers formulated using co-suspension delivery technology in patients with COPD
De Backer W, De Backer J, Verlinden I, Leemans G, Van Holsbeke C, Mignot B, et al.
Ther Adv Respir Dis . 2020 May; 14:1753466620916990. PMID: 32380894
Background: Functional respiratory imaging (FRI) is a quantitative postprocessing imaging technique used to assess changes in the respiratory system. Using FRI, we characterized the effects of the long-acting muscarinic antagonist...